Biomarkers in AL Amyloidosis

Area of Science:

• Hematology
• Oncology
• Medical Biomarkers

Background:

• Systemic AL amyloidosis is a rare hematological disorder originating from clonal plasma cells producing amyloidogenic immunoglobulins.
• Patient prognosis is influenced by the extent of organ involvement from amyloid deposition and the characteristics of the plasma cell clone.

Purpose of the Study:

• To review the current understanding of prognostic factors in systemic AL amyloidosis.
• To highlight the need for improved diagnostic and prognostic biomarkers.

Main Methods:

• Review of existing literature on systemic AL amyloidosis.
• Analysis of current staging systems and biomarkers for cardiac and renal involvement.
• Evaluation of genetic markers and minimal residual disease assessment.

Main Results:

• Cardiac dysfunction is a primary determinant of prognosis and survival.
• Renal staging systems assess the risk of end-stage renal disease.
• Clonal genetic markers, particularly from interphase fluorescence in situ hybridization, predict survival and guide treatment.
• Free light chain assessment is crucial for hematological response criteria.

Conclusions:

• Current staging systems effectively assess cardiac and renal damage but lack comprehensive disease insight.
• Genetic markers and minimal residual disease monitoring are vital for long-term management.
• Development of novel biomarkers is essential for early diagnosis and a holistic understanding of organ damage and disease biology in AL amyloidosis.